Related Articles
IDH1 mutation of gliomas with long-term survival analysis
Identification of prognostic biomarkers for glioblastomas using protein expression profiling
Diagnosis and microsurgical treatment of chondromas and chondrosarcomas of the cranial base
IDH1/2 mutation is a prognostic marker for survival and predicts response to chemotherapy for grade II gliomas concomitantly treated with radiation therapy
IDH1‑R132H mutation radiosensitizes U87MG glioma cells via epigenetic downregulation of TIGAR